Archive: 20/20 genesystems

Premium
20/20 GeneSystems has been busy. We first recommended the company in December 2017 when we learned about its incredible cancer detection technology. 20/20 GeneSystems identifies cancer risk early on by using tumor antigen markers. It can improve cancer detection by up to 30% through its proprietary machine learning algorithm. In 2020, the company pivoted to COVID testing. At its peak, 20/20 GeneSystems provided 1,200 to 1,300 tests a day. The numbers…

Startup Insider: Medical Testing’s Golden Age

By Early Investing on April 21, 2021

We have a special treat for you this week. Our First Stage Investor members (click here to sign up) regularly get to hear Andy Gordon and Vin Narayanan interview founders. This week, we’re releasing a very special interview…
Premium

Update: 20/20 GeneSystems Grows Revenue Sevenfold

By Andy Gordon on February 4, 2021

Yesterday I wrote about how the medtech and healthcare sector is seeing amazing growth. It’s one of my favorite sectors to look for promising startups in. But my love of this sector is nothing new. And today I want to give you an…

Can Coronavirus Antibody Tests Save the U.S.?

By Andy Gordon on May 6, 2020

Early Investing Co-Founder Andy Gordon checks in with an expert to figure out what’s going on with coronavirus antibody testing - and how it can help the U.S.
20/20 GeneSystems’ founder and CEO answers questions about the company moving into providing rapid COVID-19 tests.
Premium
20/20 GeneSystems founder and CEO answers questions about the company moving into providing rapid COVID-19 tests.
Premium

20/20 Prepares to Scale in the U.S. and Globally

By Andy Gordon on February 24, 2020

20/20 GeneSystems is preparing to scale both in the U.S. and globally.
Premium

20/20 GeneSystems Is on the Verge of a Big Upswing

By Andy Gordon on July 29, 2019

20/20 GeneSystems is expanding its marketing efforts and is on the verge of major revenue growth.
Premium
This week, we’re checking in with two of our portfolio companies. HyperSciences is planning a big field test of its technology, while 20/20 GeneSystems is expanding its reach.